Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial
Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial
Nahla Hasabou, Masanori Kosako, Jamie Jung-Hee An, Taishi Sakatani et al.
Journal
Annals of Hematology
Topics
Acute Myeloid Leukemia Research
article
Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial
Nahla Hasabou, Masanori Kosako, Jamie Jung-Hee An, Taishi Sakatani, Lily Wong Lee Lee, Yaru Deng, Archrob Khuhapinant, Ligen Liu, Bin Jiang, Vladimir Ivanov, Elena Martynova, Hao Jiang, Xin Du, Jianxiang Wang, Jianda Hu, Jian Li, Xiaoxi Zeng, Sergey Bondarenko
article en
Abstract
No abstract available for this paper.
Publication Tag
Annals of HematologyVol. 105(3)
Institutions
Fujian Medical University (CN), Siriraj Hospital (TH), Astellas Pharma (Japan) (JP), Shanghai Jiao Tong University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Mahidol University (TH), First Pavlov State Medical University of St. Petersburg (RU), Peking Union Medical College Hospital (CN), Federal Almazov North-West Medical Research Centre (RU), Astellas Pharma (China) (CN), Tongren Hospital (CN), Krasnoyarsk Regional Clinical Hospital (RU), Peking University People's Hospital (CN), Peking University International Hospital (CN), Second Affiliated Hospital of Fujian Medical University (CN), Institute of Hematology & Blood Diseases Hospital (CN), Guangdong Provincial People's Hospital (CN), Union Hospital (CN), Queen Elizabeth Hospital (MY), Astellas Pharma (United States) (US)